INTRODUCTION
Th ere is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the tumor vasculature with the potential to switch the tumor immune microenvironment to a more immunosupportive profi le (1) .
Th e effi cacy of anticancer immunotherapy using immune checkpoints blockade is compromised by hypoxia and poor T cell infi ltration within the tumor resulting from poor perfusion in the disorganized tumor vessels. Abnormal tumor vessels also limit the adhesion and extravasation of leukocytes and impair leukocyte infi ltration into the tumor tissue. Hypoxia increases the immunosuppressive nature of the stromal tumor microenvironment, by impairing T-cell eff ector functions including T-cell receptor signaling, proliferation, and cytokine production. Hyperoxia also increases the performance of cytotoxic T-cell, which may result in bett er clinical responses to the blockade of the immune checkpoints, e.g. programmed death receptor 1 (PD-1) (2) . Th e hypoxic tumor is genetically unstable, giving rise to a new genotype with increased production of angiogenic factors. Th is transformation, known as the angiogenic switch, initiates the angiogenesis process.
Th e inhibitors of VEGF enhance the infl ux of immune cells into the tumor by restoring vessel integrity, increasing tumor perfusion and decreasing interstitial fl uid pressure. Th e normalized tumor vasculature not only results in reduced tissue hypoxia and improved delivery of cytotoxic agents as well as oxygen (enhancing the eff ect of radiation therapy), but also augments anti-tumor immunity (3). In addition, deprivation of nutrients including glucose impedes T-cell proliferation and activation of CD8+ eff ector cells. Hence, tumor vessel normalization may be, consequently, expected to enhance the overall anticancer immunotherapy response (2) .
Th e increased antitumor immune response seen with anti-VEGF therapy might be also related to the countering of the direct and indirect immunosuppressive activity of VEGF on eff ector T cells (Fig. 1) . VEGF can inhibit the T cell function while increasing the recruitment of myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs), and suppressing the diff erentiation and activation of dendritic cells (4) . Hence, blocking VEGF sign- aling enhances eff ector T-cell function by increasing the activation and traffi cking to the tumor due to both tumor vessel normalization and by inhibiting the VEGF-induced upregulation of inhibitory immune checkpoints (3, 5) .
VASCULAR ENDOTHELIAL GROWTH FACTOR
Vascular endothelial growth factor (VEGF) has two fundamental roles, fi rst, in developing and maintaining blood vessels, and, second in regulating vascular endothelial cell permeability (6) . Immunohistochemical studies have shown that VEGF is not expressed in normal colorectal mucosa, but signifi cantly expressed in adenocarcinomas. VEGF expression is an early event in the transformation sequence from adenoma to adenocarcinoma. Neovascularization, underpinned by increased expression of VEGF is required for both tumor nutrition and hematogenous spread (7) . In colorectal adenocarcinoma high VEGF expression has been demonstrated to correlate with poor prognosis and higher incidence of liver metastases.
VEGF inhibition is used successfully in the treatment of metastatic colorectal adenocarcinoma with bevacizumab, afl ibercept and regorafenib and of advanced gastric adenocarcinoma with ramucirumab. In addition, radiosensitivity may be increased by the anti-angiogenic eff ect of bevacizumab. Bevacizumab has been incorporated into phase I-II studies of preoperative chemoradiotherapy for rectal cancer but the toxicity patt ern and surgical complications observed in some studies prevented its routine use. Th e abscence of a predictive biomarker for the therapeutic response to VEGF inhibitors means the selection of patients with a higher chance of response is currently impossible (8) .
IMMUNOSCORE
Tumor infi ltrating lymphocytes (TIL) are frequently found in colorectal tumors, indicating that these tumors are capable of triggering an immune response (9) . Th e fi nal eff ectors of antitumor adaptive immune response are predominantly cytotoxic T lymphocytes recognizing nonself antigens, leading ultimately to tumor cell killing. Several studies have reported that high abundance of CD8+ cytotoxic TIL is associated with a positive clinical outcome across various diff erent primary tumors, including non-small cell lung cancer, colorectal carcinoma, esophageal cancer, breast cancer as well as urothelial cancers and melanoma (10) .
All types of immune cell may be encountered in the tumor. Analysis of the location, density and functional orientation of diff erent immune cell populations is refered to as the immune contexture (11) . Th orough intra-tumor analysis demonstrates, that these immune infi ltrates are not distributed randomly. Th e combination of two markers (CD3+ TIL and CD8+ TIL) in two regions (center of the tumor and its invasive margin) has been validated for standard clinical practice in colorectal cancer. Th e Immunoscore is a prognostic tool, which seems superior to the tumor-node-metastasis (TNM) classifi cation in colorectal cancer (12) .
A study of three independent cohorts of 415, 119 and 69 patients with stage I-III. colorectal cancer found a significantly lower recurrence rate and longer overall survival in patients with a high density of CD3+, CD8+, CD45RO+ TIL and granzyme B. The type, density, and location of immune cells in colorectal cancer was superior to and independent of those of the UICC-TNM classification (13) .
A study in 411 patients with stage I and II colorectal cancer showed a favorable prognostic value of high-density CD8 + and CD45RO + TIL (14) .
IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF METASTATIC COLORECTAL CANCER PATIENTS
Abundant infiltration by CD8+ TIL is characteristic for colorectal cancers with microsatellite instability that represent approximately 15% of sporadic colorectal cancer cases. Microsatellite instability is caused by deficiency of DNA mismatch repair (MMR) and associated with 10-50 times higher mutational load compared to colorectal tumors without MMR defects. There is evidence that cancers with high gene mutational load respond better to immune checkpoint inhibitor therapy (15) . Tumour microsatellite instability testing is strongly asociated with response to immune checkpoint inhibitors when treating metastatic colorectal cancer patients. Patients with high microsatellite instability respond to PD-1 inhibitors (e.g. pembrolizumab or nivolumab) and PD-L1 inhibitors (e.g. atezolizumab) (16) alone or in combination with CTLA4 inhibitors (e.g. nivolumab with ipilimumab) (17, 18) . The number of clinical trials that assess the efficacy of the checkpoint inhibitors in the treatment of colorectal cancer with or without combination with radiotherapy is increasing (Table 1 
COMBINATION OF ANTI-VEGF THERAPY WITH IMMUNE CHECKPOINT INHIBITORS
The rationale of combining the VEGF blockade with the blockade of immune checkpoints has been reviewed above. This combined blockade represents an emerging strategy and probably a new standard of clinical management of renal cell carcinoma (20) . Given the activity of both anti-VEGF agents and immune checkpoint inhibitors in colorectal carcinoma, this combination therapy represents an attractive approach that is being investigated also in patients with metastatic colorectal carcinoma.
CONCLUSION
Bearing in mind the recent successes for immunotherapies, combinations of anti-VEGF therapy with immune checkpoint inhibitors now appears an attractive strategy. Key to the successful implementation of a combination strategy for treating cancer is understanding the interaction between these two therapeutic interventions, particularly in regards to appropriate reprogramming of the tumor immune microenvironment to improve antitumor immunity (2, 21) .
